ABIVAX Société Anonyme (NASDAQ:ABVX) Sees Large Growth in Short Interest

ABIVAX Société Anonyme (NASDAQ:ABVX) was the target of a large growth in short interest in June. As of June 15th, there was short interest totalling 107,900 shares, a growth of 9.3% from the May 31st total of 98,700 shares. Based on an average trading volume of 52,600 shares, the short-interest ratio is currently 2.1 days. Currently, 0.2% of the shares of the stock are short sold.

Analyst Ratings Changes

Several research firms recently issued reports on ABVX. Morgan Stanley increased their price target on shares of ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 11th. BTIG Research assumed coverage on shares of ABIVAX Société Anonyme in a report on Monday, May 20th. They set a “buy” rating and a $43.00 price target on the stock. Guggenheim assumed coverage on shares of ABIVAX Société Anonyme in a research note on Monday, April 29th. They set a “buy” rating and a $50.00 target price for the company. Finally, Piper Sandler started coverage on shares of ABIVAX Société Anonyme in a research note on Monday, April 29th. They set an “overweight” rating and a $42.00 target price for the company. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, ABIVAX Société Anonyme currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.20.

Institutional Investors Weigh In On ABIVAX Société Anonyme

A number of institutional investors have recently added to or reduced their stakes in the company. Capstone Investment Advisors LLC grew its position in ABIVAX Société Anonyme by 9.0% in the 1st quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock worth $900,000 after purchasing an additional 5,199 shares in the last quarter. BNP Paribas Financial Markets bought a new position in shares of ABIVAX Société Anonyme during the 1st quarter valued at approximately $81,000. Kennedy Capital Management LLC grew its position in shares of ABIVAX Société Anonyme by 35.3% during the 1st quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after acquiring an additional 31,331 shares during the period. Ghisallo Capital Management LLC bought a new position in shares of ABIVAX Société Anonyme during the 4th quarter valued at approximately $642,000. Finally, Janus Henderson Group PLC grew its position in shares of ABIVAX Société Anonyme by 18.2% during the 1st quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after acquiring an additional 131,414 shares during the period. 47.91% of the stock is owned by institutional investors.

ABIVAX Société Anonyme Price Performance

NASDAQ:ABVX opened at $13.50 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 4.08 and a quick ratio of 4.08. ABIVAX Société Anonyme has a one year low of $7.99 and a one year high of $17.02. The firm has a 50-day moving average of $14.02 and a 200-day moving average of $13.38.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.